Singapore’s sovereign wealth fund GIC has participated in a consortium of institutional investors, led by Hillhouse Capital Group, to invest $418 million through a private placement in Nasdaq-listed Chinese biopharma company I-Mab, according to a GIC press release.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
